RenoFi | $22,000,000 | (Mar 4, 2026)
Worldscape | Undisclosed Amount | (Mar 4, 2026)
MightyFly | $10,000,000 | (Mar 4, 2026)
Certified by Founder
Lodge
ErVimmune
start up
- 21/01/2026
- Series A
- $19,917,795
Targeting shared unconventional tumor antigens in cancer immunotherapy
- Industry Biotechnology Research
- Website https://ervimmune.com/
- LinkedIn https://www.linkedin.com/company/ervimmune/
Related People
Stéphane DEPILFounder
France -
Onco-hematologist at Centre Léon Bérard and leader of the team "Antigen presentation, T cell and Cancer" at Cancer Research Center of Lyon. Over 20 years of experience in oncology research and drug development both in academia and pharma/biotech companies as former SVP R&D and CMO at Cellectis, CEO at Netris Pharma and Head of OncologyR&D at Servier.Founder and board member of ErVimmune, a biotech company developing cancer vaccines and T cell therapies targeting non-conventional tumor epitopes.
Qura | $1,739,595 | (Mar 4, 2026)
KeyCare | $27,400,000 | (Mar 4, 2026)
Devotion(US) | $4,000,000 | (Mar 4, 2026)
Burst | $2,100,000 | (Mar 4, 2026)
JetStream Security Inc. | $34,000,000 | (Mar 4, 2026)
Escargot | $2,750,000 | (Mar 4, 2026)
EGI Battery | $10,000,000 | (Mar 4, 2026)
Bindbridge | $3,800,000 | (Mar 4, 2026)
Inhouse | $5,000,000 | (Mar 3, 2026)